Skip to Content

Mintezol Side Effects

Generic Name: thiabendazole

Note: This page contains information about the side effects of thiabendazole. Some of the dosage forms included on this document may not apply to the brand name Mintezol.

For the Consumer

Applies to thiabendazole: suspension, tablet

Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Appetite loss; bad urine odor; diarrhea; dizziness; drowsiness; dry eyes; giddiness; headache; indigestion; irritability; nausea; sensation of floating; stomach upset or pain; tiredness; vomiting; weakness; worms in mouth or nose.

Seek medical attention right away if any of these SEVERE side effects occur while taking thiabendazole (the active ingredient contained in Mintezol)

Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blood in urine; blurred vision; change in vision; chills; collapse; confusion; dark urine; depression; enlarged lymph nodes; flushing; hoarseness; increased thirst or urination; loss of coordination; numbness; red, swollen, or blistered skin; ringing in the ears; seizures; severe stomach pain; sore throat or fever; strange feeling in your eyes; uncontrolled urination; vision tinged yellow; yellowing of the skin or eyes.

For Healthcare Professionals

Applies to thiabendazole: compounding powder, oral suspension, oral tablet chewable


Gastrointestinal side effects have commonly included nausea, vomiting, anorexia, and abdominal pain. These side effects generally only last 1 to 2 days and do not require drug discontinuation. Epigastric distress and abdominal pain have also been reported.[Ref]

Nervous system

Nervous system side effects have included drowsiness, dizziness, giddiness, headache, paresthesias, weariness, numbness, hyperirritability, convulsions, collapse, confusion, depression, floating sensation, weakness, and lack of coordination.[Ref]


Erythema multiforme (including Stevens-Johnson syndrome) and toxic epidermal necrolysis generally do not occur for several weeks after thiabendazole (the active ingredient contained in Mintezol) is discontinued. The reaction generally starts with a skin eruption which quickly progresses. Two reported cases had complete recovery after several weeks of therapy.[Ref]

Hypersensitivity adverse effects have included pruritic rash reactions, fever, facial flush, chills, conjunctival injection, angioedema, anaphylaxis, skin rashes (including perianal), erythema multiforme (including Stevens-Johnson syndrome), toxic epidermal necrolysis, and lymphadenopathy.[Ref]


Sicca complex has been frequently noted with the hepatic changes associated with thiabendazole (the active ingredient contained in Mintezol) This clinical picture includes keratoconjunctivitis sicca and xerostomia. This also appears to be reversible in most cases without medical intervention.[Ref]

Hepatic side effects reported have included liver damage. It may manifest as jaundice, cholestasis, sicca syndrome, malaise, light-colored stools, and gastrointestinal upset. These symptoms generally do not occur for several weeks following thiabendazole therapy completion. Therapy usually consists of only supportive measures. In most cases the hepatic damage is reversible, although at least one patient has died as a result of hepatic damage. Sicca complex has also been reported.[Ref]


Ocular side effects have included abnormal sensation in eyes, xanthopsia, blurred vision, and transient disturbances in vision.


Cardiovascular side effects have included hypotension.


Metabolic side effects have included hyperglycemia.


Hematologic side effects have included transient leukopenia.


Genitourinary side effects have included hematuria, enuresis, malodor of the urine, and crystalluria.


Psychiatric side effects have included psychic alterations.


Other side effects have included tinnitus, drying of mucous membranes, and live Ascaris in the mouth and nose.


1. Grove DI "Treatment of strongyloidiasis with thiabendazole: an analysis of toxicity and effectiveness." Trans R Soc Trop Med Hyg 76 (1982): 114-8

2. Gann PH, Neva FA, Gam AA "A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis." J Infect Dis 169 (1994): 1076-9

3. Nauenberg W, Edelman MH, Spingarn CL "Observations on the treatment of strongyloidiasis with thiabendazole in New York City." Mt Sinai J Med 37 (1970): 607-11

4. Tanowitz HB, Wittner M "Probable thiabendazole allergy after repeated administration." J Trop Med Hyg 73 (1970): 141-2

5. Rex D, Lumeng L, Eble J, Rex L "Intrahepatic cholestasis and sicca complex after thiabendazole: report of a case and review of the literature." Gastroenterology 85 (1983): 718-21

6. Fink AI, MacKay CJ, Cutler SS "Sicca complex and cholangiostatic jaundice in two members of a family probably caused by thiabendazole." Ophthalmology 86 (1979): 1892-6

7. Roy MA, Nugent FW, Aretz HT "Micronodular cirrhosis after thiabendazole." Dig Dis Sci 34 (1989): 938-41

8. Bion E, Pariente EA, Maitre F "Severe cholestasis and sicca syndrome after thiabendazole." J Hepatol 23 (1995): 762-3

9. Manivel JC, Bloomer JR, Snover DC "Progressive bile duct injury after thiabendazole administration." Gastroenterology 93 (1987): 245-9

10. Jalota R, Freston JW "Severe intrahepatic cholestasis due to thiabendazole." Am J Trop Med Hyg 23 (1974): 676-8

Not all side effects for Mintezol may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.